Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Health Ministry Panel Agrees to Regulate Clinical Research by Law
October 24, 2014
- MHLW Orders Revision of Package Insert for Xtandi
October 24, 2014
- MHLW Orders Revision of Package Inserts for Acetaminophen
October 24, 2014
- Trade Groups Seek Insurance Coverage for Conditionally Approved Regenerative Medicine Products
October 24, 2014
- Chuikyo OKs New Review Organs for Regenerative Medicines and Medical Devices under Senshin-Iryo System
October 24, 2014
- Chuikyo Begins Discussions on Patient-Initiated Mixed-Care System
October 24, 2014
- Online Document Filings for Healthcare Product Import/Export Possible from November
October 23, 2014
- Shiozaki Sounds Positive about Fact-Finding Study for Yearly NHI Price Cuts
October 23, 2014
- NIBIO, PMDA Join Hands in Advisory Services to Bring Academic Seeds to Market
October 22, 2014
- Editor’s Pick: Five Healthcare News Headlines for October 6 - October 17
October 21, 2014
- Takeda Takes Over Development of Glatiramer Acetate from Teva: Official
October 21, 2014
- Health Ministry Eyes Future Genomic Data Registration at National Medical Centers
October 21, 2014
- Applications Based on the Revised PAL to Be Accepted from Nov. 25
October 17, 2014
- MHLW to Report Lantus Biosimilars to PAFSC First Committee on Oct. 29
October 17, 2014
- NIBIO to Begin Drug Seed Optimization Project from FY2015
October 16, 2014
- PAFSC Second Committee to Discuss Janssen’s Combination Tablet for HIV Infection on Oct. 27
October 16, 2014
- 4 Die after Taking SGLT-2 Inhibitors, Causality under Scrutiny
October 15, 2014
- Japan Faces Rocky Road to Ratify Nagoya Protocol on Biodiversity
October 15, 2014
- MHLW Panel OKs Tweaked Requirements for New Development Request Scheme
October 15, 2014
- Council OKs Public-Knowledge Based Application for Solu-Cortef as a Treatment for Bronchial Asthma
October 15, 2014
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…